RICHMOND, Calif., July 13, 2018 /PRNewswire/
-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced
that Michael Holmes, Ph.D., Senior
Vice President and Chief Technology Officer, will resign from the
Company effective July
20th to pursue an opportunity with a startup
biotech company. Edward Rebar,
Ph.D., has been named Senior Vice President and Chief Technology
Officer, effective immediately.
"We wish Michael well in his new endeavor," said Sandy Macrae, CEO of Sangamo. "We are grateful
for his contributions to Sangamo over the years and are excited for
him as he pursues this ground-floor opportunity at a biotech
startup."
Dr. Holmes joined Sangamo in 2001 as a senior scientist and over
the years has been promoted to lead many of Sangamo's research
programs. Along with Dr. Rebar and other Sangamo scientists, Dr.
Holmes made important contributions to the development of zinc
finger proteins for therapeutic, research and agricultural
applications. He was named Chief Technology Officer earlier in
2018.
Dr. Rebar joined Sangamo in 1998, and over the last 20 years he
has led the development of the Company's zinc finger protein
platform. He has authored over 60 publications relating to the
development of customized DNA binding proteins and nucleases for
genome editing. Prior to joining Sangamo, he was a
post-doctoral fellow at the University of
California, Berkeley. Dr. Rebar earned his B.S. in
Biochemistry from Rutgers University
and his Ph.D. in Biophysics and Structural Biology from
MIT.
"I'm very pleased to announce Ed
Rebar's promotion to Chief Technology Officer," Macrae said.
"During his tenure at Sangamo, Ed has led the development and
optimization of our core zinc finger technology. In the field of
genome editing he is recognized as a leader and a strong voice for
setting very high standards for editing technology being developed
for therapeutic use."
About Sangamo Therapeutics
Sangamo Therapeutics, Inc.
is focused on translating ground-breaking science into genomic
therapies that transform patients' lives using the Company's
platform technologies in genome editing, gene therapy, gene
regulation and cell therapy. For more information about Sangamo,
visit the Company's website at www.sangamo.com.
View original content with
multimedia:http://www.prnewswire.com/news-releases/sangamo-therapeutics-announces-technology-leadership-changes-300680849.html
SOURCE Sangamo Therapeutics, Inc.